Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29138552 | 0.83 | CYP4F2 (0.45) | MEN1KMT2AMAPK1NPSR1SMN1; SMN2 | |
| SCHEMBL5672910 | 0.82 | MAPK1 (0.47) | MEN1KMT2AMAPK1NPSR1SMN1; SMN2 | |
| SCHEMBL28076009 | 0.82 | PKM (0.47) | MEN1KMT2AMAPK1NPSR1SMN1; SMN2 | |
| SCHEMBL24517923 | 0.81 | MAPK1 (0.44) | MEN1KMT2AMAPK1NPSR1SMN1; SMN2 | |
| SCHEMBL28076010 | 0.79 | MAPK1 (0.44) | MEN1KMT2AMAPK1NPSR1SMN1; SMN2 | |
| SCHEMBL27590315 | 0.79 | PKM (0.45) | MEN1KMT2AMAPK1NPSR1SMN1; SMN2 | |
| SCHEMBL6964768 | 0.79 | PKM (0.45) | MEN1KMT2AMAPK1NPSR1SMN1; SMN2 | |
| SCHEMBL7279894 | 0.77 | SMN1; SMN2 (0.40) | MEN1KMT2AMAPK1NPSR1SMN1; SMN2 | |
| SCHEMBL7094417 | 0.76 | MAPK1 (0.44) | MEN1KMT2AMAPK1NPSR1SMN1; SMN2 | |
| SCHEMBL5539302 | 0.76 | MAPK1 (0.41) | MAPK1NPSR1SMN1; SMN2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105541752-B | The preparation method of the acetogenin of 2 (imino group of 4 oxothiazoiium quinoline 2) thiazole 4 and application | 湖南大学 | 2017-08-04 | — | — | CN | claimed |
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-121554891-A | High-skid-resistance PVC floor and preparation method thereof | 保定巨恒塑料制造有限公司 | 2026-02-24 | — | — | CN | disclosed |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| WO-2024229317-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-04-25 | — | — | US | disclosed |
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | disclosed |
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| CN-112888696-B | Exonuclease inhibitors and methods of use thereof | 德琪医疗有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-0986384-A4 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |
| EP-0986384-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1999031096-A1 | PIPERAZINE DERIVATIVES USEFUL AS HYPOGLYCEMIC AGENTS | SHAMAN PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1998050029-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| US-4282220-A | Cephem derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-08-04 | — | — | US | disclosed |
| US-4001241-A | GASTRIC ACID, ANTISECRETORY AGENTS | SMITHKLINE CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-3966945-A | 2-Alkoxy(and 2-alkoxyalkyl)-2-heterocyclic-thioacetamides for inhibiting gastric acid secretion | SMITHKLINE CORPORATION (US) | 1976-06-29 | — | — | US | disclosed |
| US-3956494-A | ANTISECRETORY AGENTS, HETEROCYCLIC THIOPROPIONAMIDES | SMITHKLINE CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
| US-3948892-A | 2-Alkoxy(and 2-amino)-3-amino-2-heterocyclic-thiopropanamides | SMITHKLINE CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | MEN1 1731/4885KMT2A 3055/4885MAPK1 4119/4885 |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | MEN1 2619/4885KMT2A 701/4885MAPK1 201/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | MEN1 1731/4885KMT2A 3055/4885MAPK1 4119/4885 |
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | MEN1 3431/4885KMT2A 578/4885MAPK1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.